{"id":2893,"date":"2026-08-25T13:02:56","date_gmt":"2026-08-25T12:02:56","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/fr\/?post_type=product&p=2893"},"modified":"2026-08-25T13:02:56","modified_gmt":"2026-08-25T12:02:56","slug":"buy-mod-grf-1-29-ghrp-6-blend-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/fr\/product\/buy-mod-grf-1-29-ghrp-6-blend-in-switzerland\/","title":{"rendered":"Mod GRF 1-29 & GHRP-6 Blend (10MG)"},"content":{"rendered":"

What Is the Mod GRF 1-29 & GHRP-6 Blend and Why Buy It for Research?<\/strong><\/h2>\n

Buy Mod GRF 1-29 & GHRP-6 Blend in Switzerland for research into growth hormone axis signaling, synergistic GH release, and orexigenic pathways. Specifically, this 10mg research formulation combines two complementary growth hormone secretagogues in a single pre-mixed lyophilized vial: Mod GRF 1-29 (CJC-1295 without DAC, 5mg) and GHRP-6 (5mg). This blend pairs a growth hormone-releasing hormone (GHRH) analog with a potent growth hormone secretagogue (GHS) to probe convergent pathways in the GH-IGF-1 axis.<\/p>\n

Mod GRF 1-29 (without DAC, also known as CJC-1295 without DAC or Modified GRF 1-29) is a synthetic 29-amino acid peptide analog of GHRH that activates the GHRH receptor on anterior pituitary somatotrophs, driving cAMP\/PKA-mediated GH synthesis and secretion. GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide that engages the GHS-R1a receptor (ghrelin receptor), mobilizing intracellular calcium to trigger GH granule release. GHRP-6 is the original and most thoroughly studied growth hormone-releasing hexapeptide. When combined, these two peptides produce synergistic GH release\u2014significantly higher than either compound alone. Furthermore, Core Peptides supplies this blend as a lyophilized powder in a 10mg format exclusively for laboratory use. Therefore, researchers seeking to source this combination for their work will find it readily available when they buy Mod GRF 1-29 & GHRP-6 Blend in Switzerland.<\/p>\n

Mod GRF 1-29 & GHRP-6 Blend Research Overview: Buy Mod GRF 1-29 & GHRP-6 Blend in Switzerland for GH Axis Studies<\/strong><\/h2>\n

Centrally, research into the Mod GRF 1-29 and GHRP-6 blend has focused on the complementary and synergistic mechanisms of its two components. The foundational observation that GHRH + GHRP produces synergistic GH release was established in human subjects, demonstrating that co-administration of GHRH and GHRP produced GH peaks significantly higher than either peptide alone.<\/p>\n

Mod GRF 1-29 functions as a GHRH analog that binds to the GHRH receptor (GHRH-R), a G-protein coupled receptor (GPCR) on pituitary somatotrophs. The peptide incorporates four strategic amino acid substitutions at positions 2 (Ala to D-Ala), 8 (Asn to Gln), 15 (Gly to Ala), and 27 (Met to Leu), which confer resistance to DPP-IV cleavage and other degradation pathways, extending the biological half-life from less than 7 minutes (native GHRH) to approximately 30 minutes. This binding activates a downstream signaling cascade that results in GH synthesis and release.<\/p>\n

GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH\u2082. It acts directly on specific pituitary receptors and indirectly on the hypothalamus, stimulating endogenous GHRH release from arcuate nucleus neurons and functionally suppressing somatostatin release. A characteristic and clinically relevant effect of GHRP-6 is a consistent appetite-stimulating response, reflecting strong orexigenic signaling through the ghrelin pathway. GHRP-6 has a molecular weight of 873.0 g\/mol, the molecular formula C\u2084\u2086H\u2085\u2086N\u2081\u2082O\u2086, and a CAS number of 87616-84-0.<\/p>\n

When combined, Mod GRF 1-29 sustains physiologic pulsatile GH secretion while GHRP-6 amplifies output through hypothalamic effects and suppression of somatostatin. GHRP-6 stacks synergistically with GHRH analogs to produce multiplicative GH elevation exceeding either peptide alone. The synergy works through amplitude (GHRP-6) plus frequency (GHRH analog). Accordingly, researchers who buy Mod GRF 1-29 & GHRP-6 Blend in Switzerland from Core Peptides can support their investigations into GH axis signaling, synergistic peptide interactions, and orexigenic pathways.<\/p>\n

How Does the Mod GRF 1-29 & GHRP-6 Blend Work in Research?<\/strong><\/h2>\n

Mechanistically, the Mod GRF 1-29 and GHRP-6 blend operates through two complementary signaling pathways that converge on GH release from pituitary somatotrophs.<\/p>\n

GHRH Receptor Pathway (Mod GRF 1-29)<\/strong><\/h3>\n

Mod GRF 1-29 activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, driving cAMP\/PKA-mediated GH synthesis and secretion. It functions as a stable and active hGRF1-29 analog with a half-life of approximately 30 minutes. The amino acid substitutions at positions 2, 8, 15, and 27 confer resistance to DPP-IV cleavage, extending the effective half-life compared to native GHRH. This binding initiates a downstream signaling cascade that results in GH synthesis and release.<\/p>\n

GHS-R1a Pathway (GHRP-6)<\/strong><\/h3>\n

GHRP-6 binds the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor, through Gq\/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. GHRP-6 is a potent agonist of GHS-R1a and has been shown to have GH-releasing activity comparable to or greater than that of GHRH. Beyond somatotroph GH release, GHRP-6 activates hypothalamic circuits that suppress somatostatin release and stimulate endogenous GHRH secretion, creating a feed-forward loop that further amplifies GH output. Research demonstrates that GHRP-6 raises the basal set-point of GH secretion, effectively elevating the trough level. As an additional benefit, GHRP-6 stimulates appetite through ghrelin-pathway activation.<\/p>\n

Synergistic Effects<\/strong><\/h3>\n

The dual combination produces synergistic (not merely additive) GH release. Mod GRF 1-29 sustains physiologic pulsatile GH secretion while GHRP-6 amplifies output through hypothalamic effects and suppression of somatostatin. GHRP-6 works by activating GHS-R1a receptors on pituitary cells, triggering one specific signaling pathway (Gq\/Gi G-protein coupled). At the same time, Mod GRF 1-29 works by activating GHRH receptors on the same pituitary cells, triggering a different signaling pathway (Gs G-protein coupled). When both pathways are activated simultaneously, the result is multiplicative\u2014far greater than either pathway alone. Furthermore, GHRP-6 actively antagonizes somatostatin, the hormone that inhibits growth hormone release. Mod GRF 1-29 then drives pulsatile GH release from the elevated baseline, preserving the physiologic secretory pattern even under sustained stimulation.<\/p>\n

Why Is the Mod GRF 1-29 & GHRP-6 Blend Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study this blend because it represents a well-characterized dual combination of complementary GH secretagogues that enables investigation of synergistic GH release, metabolic regulation, and orexigenic pathways. In fact, this pre-mixed blend offers a practical way to study convergent GH axis signaling without the need to source and reconstitute each compound separately.<\/p>\n

Research has demonstrated the blend’s relevance across multiple domains. GH pulse amplitude is a key determinant of recovery-relevant downstream effects including IGF-1 elevation, protein synthesis stimulation, lipolysis, and collagen synthesis. Research in GH-deficient models demonstrates that pulsatile GH administration is more effective than continuous infusion for promoting lean body mass and reducing adiposity, supporting the value of high-amplitude pulse protocols. Furthermore, GHRP-6’s broader hypothalamic effects\u2014including somatostatin suppression, endogenous GHRH stimulation, and appetite stimulation\u2014provide additional mechanisms for amplifying GH output and supporting anabolic actions. Studies suggest that the increased GH levels from this peptide blend might stimulate protein synthesis, potentially enhancing muscle cell mass and contractile force. Ultimately, researchers who buy Mod GRF 1-29 & GHRP-6 Blend in Switzerland gain access to a comprehensive research tool for investigating GH axis signaling, metabolic regulation, and orexigenic pathways.<\/p>\n

Mod GRF 1-29 & GHRP-6 Blend Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nKey Components<\/th>\n<\/tr>\n<\/thead>\n
GH Axis Signaling<\/td>\nDual-pathway activation, GHRH\/GHS receptor crosstalk, pulsatile secretion<\/td>\nBoth (complementary pathways)<\/td>\n<\/tr>\n
Metabolic Regulation<\/td>\nIGF-1 elevation, lipolysis, protein synthesis, metabolic homeostasis<\/td>\nBoth (GH-dependent effects)<\/td>\n<\/tr>\n
Orexigenic Signaling<\/td>\nAppetite stimulation, ghrelin pathway activation, energy balance<\/td>\nGHRP-6<\/td>\n<\/tr>\n
Hypothalamic-Pituitary Axis<\/td>\nSomatostatin suppression, endogenous GHRH release, feed-forward amplification<\/td>\nGHRP-6<\/td>\n<\/tr>\n
Receptor Pharmacology<\/td>\nGHRH-R, GHS-R1a binding, receptor binding kinetics, dual-receptor activation<\/td>\nBoth (distinct targets)<\/td>\n<\/tr>\n
Pulsatile GH Secretion<\/td>\nPhysiologic GH patterning, amplitude modulation, pulse dynamics<\/td>\nMod GRF 1-29<\/td>\n<\/tr>\n
Tissue Repair and Regeneration<\/td>\nCollagen synthesis, chondrocyte proliferation, connective tissue repair<\/td>\nBoth<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Mod GRF 1-29 & GHRP-6 Blend Compared With Related Research Formulations<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Formulation<\/th>\nComponents<\/th>\nResearch Focus<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
Mod GRF 1-29 + GHRP-6 Blend<\/td>\nMod GRF 1-29 + GHRP-6 (1:1)<\/td>\nGH axis, synergistic release, appetite modulation<\/td>\nClassic GH stack; significant appetite stimulation via GHRP-6<\/td>\n<\/tr>\n
Mod GRF 1-29 + GHRP-2 Blend<\/td>\nMod GRF 1-29 + GHRP-2<\/td>\nGH axis, synergistic release, metabolic regulation<\/td>\nStronger GH release, more cortisol\/prolactin elevation<\/td>\n<\/tr>\n
Mod GRF 1-29 + Ipamorelin Blend<\/td>\nMod GRF 1-29 + Ipamorelin<\/td>\nGH release, metabolic regulation<\/td>\nWeaker GH pulse; minimal cortisol\/prolactin spillover<\/td>\n<\/tr>\n
Mod GRF 1-29 + Hexarelin Blend<\/td>\nMod GRF 1-29 + Hexarelin<\/td>\nGH axis, cardioprotection<\/td>\nHexarelin adds CD36 cardioprotection<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, the Mod GRF 1-29 and GHRP-6 blend differs from other GHRH\/GHS combinations in its potency and appetite-stimulating effects. On the one hand, GHRP-6 is the original and most thoroughly studied GHRP, generating robust GH output alongside significant appetite stimulation through ghrelin pathway activation. On the other hand, the Mod GRF 1-29 and Ipamorelin blend provides selective GH release with minimal cortisol elevation. In contrast, the Mod GRF 1-29 and GHRP-2 blend generates stronger GH release with more cortisol and prolactin elevation, while the Mod GRF 1-29 and Hexarelin blend adds CD36-mediated cardioprotection.<\/p>\n

Research Applications for the Mod GRF 1-29 & GHRP-6 Blend in Switzerland<\/strong><\/h2>\n

Scientists have investigated this peptide blend across several research domains:<\/p>\n